Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

198.23 -0.70 (-0.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
The Latest Analyst Ratings for Natera
 
Via Benzinga
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
From Natera, Inc.
Via Business Wire
Analyst Expectations for Natera's Future
 
Via Benzinga
Analyst Ratings for Natera
 
Via Benzinga
Top 5 Health Care Stocks That May Collapse In November
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Natera Announces Real-World Data Collaboration with Merck
From Natera, Inc.
Via Business Wire
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Natera Reports Third Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
Natera to Participate in November Investor Conferences
From Natera, Inc.
Via Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
From Kahn Swick & Foti, LLC
Via Business Wire
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
From Natera, Inc.
Via Business Wire
Bull Of The Day: NeoGenomics
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
Updated Data from CIRCULATE-Japan Presented at ESMO 2023 Reinforces Signatera’s Prognostic and Predictive Value in Analysis of 2,500+ Colorectal Cancer Patients
From Natera, Inc.
Via Business Wire
Natera to Report its Third Quarter 2023 Results on November 8
From Natera, Inc.
Via Business Wire
Natera Recognized on U.S. News & World Report’s 2024 Best Companies to Work for in Healthcare Ranking
From Natera, Inc.
Via Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Natera to Present New Signatera™ MRD Data at ESMO 2023, Featuring Large, Updated Analysis from CIRCULATE-Japan Study
From Natera, Inc.
Via Business Wire
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
From Kahn Swick & Foti, LLC
Via Business Wire
New MRD Publication in Unresectable Stage I-III Lung Cancer Demonstrates Signatera’s Ability to Risk Stratify and Detect Progression Early
From Natera, Inc.
Via Business Wire
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
From Natera, Inc.
Via Business Wire
Natera Submits First PMA Module to the FDA for Signatera™
From Natera, Inc.
Via Business Wire
Natera Announces Senior Leadership Appointments
From Natera, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
 
Via Benzinga
Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
From Natera, Inc.
Via Business Wire
Natera Announces Pricing of $250 Million Follow-On Offering
From Natera, Inc.
Via Business Wire
Natera Launches Proposed Follow-On Offering
From Natera, Inc.
Via Business Wire
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.